Latest Headlines

Latest Headlines

BioBlast sets sights on PhIII after efficacy prompts early halt of mid-stage study

BioBlast Pharma has posted a glimpse at the data that prompted it to wrap up a Phase II trial after enrolling just one-third of the targeted number of patients. And while there is very little data available publicly to support BioBlast's optimism, the company thinks it has a strong enough hand to start discussing a Phase III trial with FDA.  

Oryzon raises €17M ahead of planned IPO

Oryzon Genomics has topped up its bank balance through a private placement months ahead of its anticipated listing on the Madrid Stock Exchange. The €16.6 million ($18.4 million) investment gives Oryzon the cash to keep pushing ahead with its pipeline plans in the months until it goes public.  

Grifols lands €100M EU loan to bankroll Alzheimer's R&D

Grifols has become one of the first companies to receive cash under the €315 billion (€344 billion) Juncker Investment Offensive. The €100 million the European Investment Bank is funneling into Grifols will support a ratcheting up of R&D into the use of plasma proteins to treat Alzheimer's and other diseases.

Ipsen strikes $137M deal for rights to bladder cancer drug

Ipsen has picked up the rights to Telesta Therapeutics' bladder cancer drug in Europe and other ex-U.S. markets in a deal worth up to $137 million (€124 million). Having acquired the rights for $10 million upfront, Ipsen is now gearing up for talks with regulators about plotting a path to approval for the drug.

Spain's Grifols opening $100M warehouse, labeling operation in Dublin

Spanish blood plasma specialist Grifols is opening a $100 million operations center in Dublin that will support its supply chain. The new operation will add dozens to Ireland's pharma sector even as Pfizer is doing the same by boosting its workforce at three plants in Ireland.

Acacia nixes £150M IPO as London wobbles; Spirogen team reforms to found ADC biotech

In this week's EuroBiotech Report, the downturn in the IPO market in London claimed its biggest biopharma casualty to date when Acacia Pharma postponed its planned £150 million ($231 million) listing shortly after fellow British biopharma Shield Therapeutics backed away from its own £110 million IPO. And more.

Noxxon files for IPO to take tumor microenvironment modulator toward PhIII

Noxxon Pharma has become the latest German biotech to head to Amsterdam in search of money from public investors. The company is seeking cash to bankroll the advance of NOX-A12, a drug designed to boost the effectiveness of other treatments through modulation of the tumor microenvironment.

AIT pushes ahead with plans for $40M Nasdaq IPO

Advanced Inhalation Therapies (AIT) has become the latest biotech to push ahead with plans to float on Nasdaq in the face of mounting evidence that investors are cooling on such offerings. The company is hoping its mix of Wall Street experience in the C-suite and upcoming clinical trial data readouts will make it an attractive proposition to investors.

Insiders help Strongbridge limp to a downsized $25M IPO

Strongbridge Biopharma has struggled through choppy conditions to complete a $25 million (€22 million) listing on Nasdaq. The rare disease player pulled off the dramatically downsized IPO by relying heavily on the support of existing shareholders, who snapped up 80% of all the shares sold.

Acacia postpones £150M IPO as London market for big listings dries up

Less than two weeks after Shield Therapeutics pulled the plug on its £110 million ($170 million) IPO, Acacia Pharma has backed away from its plan to raise £150 million by listing on the London Stock Exchange.